Chloe Ramirez
The Oncept vaccine is a USDA-approved treatment for stage II to III canine oral melanoma. It is a xenogeneic DNA vaccine that targets the tyrosinase protein, which is present in most melanomas. While the vaccine appears safe, data on its efficacy is mixed, and its use is controversial in the veterinary community. The vaccine is designed to prevent the metastasis of melanoma and lengthen survival time. It is meant to be used in conjunction with traditional therapies such as surgery and radiation. Some dogs seem to benefit from the vaccine, while others do not. There is currently no perfect biomarker to help predict which dogs will benefit from the treatment. While Oncept has been studied for use in dogs, it has also been evaluated for safety in cats, with some adverse events reported.
| Characteristics | Values |
|---|---|
| Name of Vaccine | Oncept |
| Type of Vaccine | Xenogeneic DNA vaccine targeting tyrosinase |
| Treatment of | Stage II to III canine oral melanoma |
| Used for | Melanomas arising in other locations and in other species |
| Safety | Safe for use |
| Effectiveness | Mixed results |
| Use case | Dogs with stage II (2 cm to < 4 cm diameter tumor, no metastasis) or stage III (4 cm or greater diameter tumor, metastasis to local lymph nodes) |
| Side effects | Mild to moderate pain at the injection site, cutaneous wheal formation, or rarely hematoma |
| Long-term effects | Mitigate the risk of tumor recurrence and metastasis of melanoma cancer cells |
| Tumor types | Lymphoma, osteosarcoma, hemangiosarcoma, and mast cell tumors (mastocytomas) |
Explore related products
What You'll Learn
Oncept is a xenogeneic DNA vaccine targeting tyrosinase
The Oncept vaccine is USDA-approved for the treatment of stage II to III canine oral melanoma and is sometimes used off-label for melanomas in other locations and species. Its use is somewhat controversial in the veterinary community due to mixed published data on its survival benefits. While some studies suggest improved survival rates, others show no significant difference between vaccinated and unvaccinated dogs. However, it is generally considered safe, with only low-grade local toxicity reported in a small number of patients.
The first clinical study of Oncept involved 58 dogs with stage II or III oral melanoma. Locoregional disease control was achieved through surgery and radiation therapy, and the Oncept vaccine was administered as an adjunctive treatment. No systemic toxicity was observed, although local side effects such as pain at the injection site and cutaneous wheal formation occurred in some cases.
The vaccine's mechanism of inducing an immune response and the conserved nature of tyrosinase suggest it should be effective across multiple species. A 2015 study evaluated the safety of Oncept in cats, reporting mostly low-grade adverse events such as pain, hyperpigmentation, and decreased appetite. However, the study did not address the vaccine's efficacy or survival rates due to variations in treatment modalities.
While Oncept specifically targets melanoma, there is ongoing research into developing a universal "cancer vaccine" as a preventive measure for various canine cancers, including mast cell tumors. These studies, conducted by veterinary colleges in Wisconsin, California, and Colorado, aim to create a vaccine that targets abnormal cells containing proteins not found in healthy dog cells. This approach holds promise for treating and preventing a range of deadly canine cancers.
Antivaxxers Claim Aborted Fetuses in Vaccines: Truth or Myth?
You may want to see also
Explore related products
Oncept is USDA-approved for stage II to III canine oral melanoma
The Oncept melanoma vaccine is a xenogeneic DNA vaccine targeting tyrosinase. It is USDA-approved for the treatment of stage II to III canine oral melanoma and is also used off-label for melanomas arising in other locations and in other species.
Oncept is a vaccine that is used to treat melanoma, a cancer of pigmented cells that can spread throughout the body, in dogs and other veterinary species. Melanomas in dogs tend to occur in dark-pigmented dogs such as Scottish Terriers and are not directly related to sun exposure. If the melanoma appears in the mouth or nail beds, it tends to be very aggressive with a rapid spread to local lymph nodes and the lungs.
The Oncept vaccine was designed to prevent metastases of melanoma. It includes DNA from the human melanocyte protein tyrosinase. Human tyrosinase is similar to the same enzyme in dogs and is part of pigment production. It is present in most melanomas. So when this vaccine is given, the dog mounts an immune response that cross-reacts to both the human and canine tyrosinase, and goes after any melanoma cells.
The first clinical study evaluating the efficacy of Oncept in canine patients evaluated 58 patients with WHO stage II or III, histologically confirmed oral melanoma. In this study, locoregional disease control was achieved with surgery and radiation therapy if necessary based on incomplete margins. Patients receiving Oncept were prospectively enrolled at multiple veterinary oncology centers throughout the United States. No systemic toxicity was seen after administration; local toxicity included mild to moderate pain at the injection site, cutaneous wheal formation, or rarely hematoma. No adverse events required veterinary intervention.
While the vaccine appears safe, the published data is mixed as to whether it provides a survival benefit, and the use of the vaccine is somewhat controversial in the veterinary oncology community.
Vaccine Exemptions: Kids' Rights in Public Schools
You may want to see also
Explore related products
$21.99
Oncept is used off-label for other melanomas and species
Oncept is a vaccine used to treat melanoma, a cancer of pigmented cells that can spread throughout the body. It is USDA-approved for the treatment of stage II to III canine oral melanoma. However, it is also used off-label for melanomas in other locations and species.
The Oncept melanoma vaccine is a xenogeneic DNA vaccine that targets tyrosinase, an enzyme involved in pigment production. This vaccine includes DNA from the human melanocyte protein tyrosinase, which is similar to the enzyme in dogs and is present in most melanomas. When administered, the vaccine induces an immune response that targets both human and canine tyrosinase, attacking any melanoma cells.
The use of Oncept for melanomas outside of oral cavity has been evaluated in various studies. For example, a 2011 study by Manley et al. examined 58 dogs with melanoma arising from the nail bed and haired skin of the digit. While the majority of these dogs also underwent digit amputation, the overall median survival time was 351 days from the time of vaccination. Another study by Ottnod et al. retrospectively evaluated 45 dogs with locoregional control of oral melanoma achieved through surgery and, if necessary, radiation therapy. Twenty-two of these dogs received Oncept as an adjuvant treatment, but there was no significant difference in PFS, DFI, and MST between the vaccinated and unvaccinated dogs.
The safety and efficacy of Oncept have also been evaluated in other species. A 2015 study investigated the safety of Oncept in 24 cats with malignant melanoma, reporting 13 grade 1 or 2 adverse events such as pain at the injection site, hyperpigmentation, and decreased appetite. While this study did not address the efficacy of the vaccine, it suggested that Oncept may be safe for use in cats. Cutaneous melanoma is also common in horses, with a prevalence of up to 80% in gray, adult horses. While most cases are considered benign, they can become more malignant if left untreated.
Overall, while Oncept has shown promise in treating melanomas in various locations and species, further studies are needed to fully evaluate its efficacy and explore other treatment options.
Attenuated Vaccines: Immune Response Magnitude
You may want to see also
Explore related products
Published data on the efficacy of Oncept is mixed
The published literature on the use of Oncept is mixed, with some studies showing significant benefits and others showing none. Some dogs seem to benefit from the vaccine, while others do not. Dogs that receive the vaccine in combination with other treatments, such as surgery and radiation therapy, tend to fare better. Tumor size and invasiveness are also factors that can help guide treatment decisions. However, there is currently no perfect biomarker to predict which dogs will benefit from the vaccine and which will not.
A study by Ottnod et al. retrospectively evaluated 45 dogs with locoregional control of oral melanoma achieved by surgery, with radiation therapy used as needed for incomplete margins. Twenty-two of the 45 dogs received Oncept as an adjuvant after locoregional treatment. The PFS, DFI, and MST were not statistically significant between vaccinated and unvaccinated dogs.
Another study evaluated the efficacy of Oncept in 58 patients with WHO stage II or III, histologically confirmed oral melanoma. Locoregional disease control was achieved with surgery and radiation therapy if necessary based on incomplete margins. No systemic toxicity was observed after administration, and local toxicity was mild to moderate. To evaluate survival, the 58 Oncept-treated dogs were compared to a historical control population of 53 dogs who achieved locoregional disease control via surgery.
While the vaccine appears safe, its efficacy remains questionable, and its use is somewhat controversial in the veterinary oncology community. Further clinical trials, such as prospective, randomized controlled trials, are needed to advance scientific knowledge and better understand patient response to Oncept.
MMR Vaccine Ingredients: What's Inside the Shot?
You may want to see also
Explore related products
$12.99
Oncept is generally safe with only local toxicity reported in some patients
Oncept is a canine melanoma vaccine that has been USDA-approved for the treatment of stage II to III canine oral melanoma. It is also used off-label for melanomas in other locations and species. The vaccine is designed to prevent metastases of melanoma and lengthen survival time. It targets about 30 proteins found on cancer cells as a result of mutations, which are not found on healthy dog cells.
Oncept is generally considered safe, with only local toxicity reported in some patients. Across multiple studies and species, only low-grade local toxicity has been reported in a small number of patients. Local toxicity includes mild to moderate pain at the injection site, cutaneous wheal formation, or rarely, hematoma. No adverse events required veterinary intervention.
In a clinical study evaluating the efficacy of Oncept in canine patients, 58 patients with WHO stage II or III, histologically confirmed oral melanoma were treated with Oncept. Locoregional disease control was achieved with surgery and radiation therapy if necessary. No systemic toxicity was observed, and the dogs treated with Oncept had a longer survival rate and improved quality of life compared to dogs that did not receive the vaccine.
However, the published data on the efficacy of the Oncept vaccine is mixed, and its use is somewhat controversial in the veterinary oncology community. Some studies show a significant benefit, while others do not. It is important to note that not all dogs will be good candidates for the vaccine, and a veterinary oncologist should be consulted to determine the best course of treatment.
Pneumococcal Vaccine Records: Who Keeps Them?
You may want to see also
Frequently asked questions
The Oncept vaccine is a xenogeneic DNA vaccine targeting tyrosinase. It is USDA-approved for treating stage II to III canine oral melanoma and is also used off-label for other types of melanoma.
The Oncept vaccine uses a human gene for tyrosinase to code a DNA vaccine that is produced with canine DNA. This stimulates the canine immune system to recognize and target melanoma cells with foreign proteins, limiting their proliferation and activity.
The Oncept vaccine is specifically designed for treating melanoma in dogs and has shown to be safe and effective in increasing survival time. While it does not directly cure mast cell tumors, it can be used in combination with other treatments such as surgery and radiation therapy to improve overall survival rates and quality of life.
